Abdal R. Abu Farhan
Catanzaro, 88100, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin Immunotherapy.
Journal: Diagnostics (Basel, Switzerland)
Published: February 05, 2022
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy.
Journal: Future oncology (London, England)
Published: July 19, 2021
Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer.
Journal: Translational andrology and urology
Published: March 15, 2021
Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy.
Journal: Future science OA
Published: January 15, 2021
Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study.
Journal: Minerva urology and nephrology
Published: January 13, 2021
Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor.
Journal: Urologic oncology
Published: July 11, 2019
High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study.
Journal: Urologia internationalis
Published: April 17, 2018
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer.
Journal: Clinical genitourinary cancer
Published: March 09, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026